Bicara Therapeutics, Inc. (BCAX)
22.02
-0.62
(-2.74%)
USD |
NASDAQ |
Sep 21, 16:00
22.02
0.00 (0.00%)
After-Hours: 20:00
Bicara Therapeutics Shareholders Equity (Quarterly) : 468.77M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 468.77M |
| March 31, 2026 | 513.96M |
| December 31, 2025 | 401.45M |
| September 30, 2025 | 402.78M |
| June 30, 2025 | 435.20M |
| March 31, 2025 | 458.96M |
| Date | Value |
|---|---|
| December 31, 2024 | 491.88M |
| September 30, 2024 | 509.56M |
| June 30, 2024 | 192.50M |
| March 31, 2024 | |
| December 31, 2023 | 218.51M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 465.53M |
| Oncolytics Biotech, Inc. | -6.167M |
| Sangamo Therapeutics, Inc. | -18.96M |
| Sarepta Therapeutics, Inc. | 1.528B |
| Anixa Biosciences, Inc. | 14.47M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 512.24M |
| Total Liabilities (Quarterly) | 43.48M |
| Debt to Equity Ratio | 0.0025 |
| Current Ratio | 11.59 |
| Net Debt Paydown Yield | -0.01% |